Comparison of Statins in Hypertriglyceridemia
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In 1996, the first 2 studies using 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor ("statin") therapy in hypertriglyceridemic subjects were published. In subjects with isolated triglyceride elevations who were treated with atorvastatin 5, 20, and 80 mg/day, large and dose-related reductions were noted. In subjects with combined hyperlipidemia treated with 10 mg simvastatin, triglyceride reduction similar to that reported for the 5 mg atorvastatin dose was seen. In response to these findings, we conducted comparative assessments to determine whether all statins are effective in lowering triglyceride levels and whether their effect on triglycerides is related to factors such as drug, dose, and baseline triglyceride levels. To standardize these assessments, we devised a ratio that related changes in triglyceride levels to the known predictable response of low-density lipoprotein (LDL) cholesterol to statins. This triglyceride/LDL cholesterol ratio was obtained by dividing the percent change from baseline in the triglyceride level by the percent change from baseline in the LDL cholesterol level. The triglyceride/LDL cholesterol ratio was initially applied to several published studies, and found to be approximately 1.0 and 0.5 in hypertriglyceridemic and nonhypertriglyceridemic populations, respectively. We then assessed the effect of various statins on triglycerides using a pooled laboratory database of 2,689 subjects who had participated in 7 separate studies…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Minimal reduction in TG in individuals with baseline TG ,150 mg/dL”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [131]
In the citing paper
“Because of the relatively constant LDL-C/triglyceride-lowering ratio for various statins, the greater the LDL-C lowering, the greater the effect on individual triglyceride levels (110).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [110]
In the citing paper
“It is also well known that statins also have a triglyceride-lowering effect [83].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [83]
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Arky, R. A. (1994) · Cited by 2,632
HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 758
Nawrocki, J. W., Weiss, S. R., Davidson, M. H., Sprecher, D. L., Schwartz, S. L., Lupien, P.-J., Jones, P. H., Haber, H. E., & Black, D. M. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.678 · Cited by 484
Bakker-Arkema, R. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530260042029 · Cited by 407
Dart, A., Jerums, G., Nicholson, G., d'Emden, M., Hamilton-Craig, I., Tallis, G., Best, J., West, M., Sullivan, D., Braes, P., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00280-4 · Cited by 187
&NA; (1995) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-199505000-00010 · Cited by 166
Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients
Pfeffer, M. A., Sacks, F. M., Moyé, L. A., Brown, L., Rouleau, J. L., Hartley, L. H., Rouleau, J. R., Grimm, R. H., Sestier, F., Wickemeyer, W. J., et al. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80478-0 · Cited by 125
Cited by
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312
Current Perspectives on Statins
Maron, D. J., Fazio, S., & Linton, M. F. (2000) · Circulation · doi:10.1161/01.cir.101.2.207 · Cited by 1,213
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Statins: mechanism of action and effects
Stancu, C., & Sima, A. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00172.x · Cited by 911
“Efficacy on triglyceride reduction parallels LDL cholesterol reduction [10].”
BackgroundSandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
“Statins (131) Dose-dependent reductions in TG of 22%–45% in individuals with baseline”
Background
Metadata
- Authors
- Stein, E. A., Lane, M., & Laskarzewski, P.
- Corresponding author
- Stein, Evan A
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 1998-02
- Volume
- 81
- Issue
- 4
- Pages
- 66B-69B
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W2007746673
- Cited by
- 386
- References
- 11
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 9 · 2022: 9 · 2021: 8 · 2020: 5 · 2019: 6 · 2018: 7 · 2017: 2 · 2016: 9 · 2015: 7 · 2014: 14 · 2013: 13 · 2012: 13
- FWCI
- 40.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- statins, hypertriglyceridemia, triglyceride lowering, atorvastatin, simvastatin, dose-response relationship, mixed dyslipidemia, drug comparison
- MeSH terms
- Atorvastatin, Anticholesteremic Agents, Clinical Trials as Topic, Heptanoic Acids, Humans, Cholesterol, LDL, Pyrroles, Triglycerides, Hypertriglyceridemia, Randomized Controlled Trials as Topic, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Statins in Hypertriglyceridemia. https://app.cochat.ai/papers/10.1016/s0002-9149(98)00041-1
- The paper
- Stein, E. A., Lane, M., & Laskarzewski, P. (1998). Comparison of Statins in Hypertriglyceridemia. The American Journal of Cardiology. https://doi.org/10.1016/s0002-9149(98)00041-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.